Efficacy News and Research

RSS
Gene therapy does not slow or halt progression of cell loss in Leber congenital amaurosis

Gene therapy does not slow or halt progression of cell loss in Leber congenital amaurosis

Galectin Therapeutics' GR-MD-02 reverses diabetic nephropathy in preclinical study

Galectin Therapeutics' GR-MD-02 reverses diabetic nephropathy in preclinical study

IntelliCell receives U.S. patent allowance for ultrasonic cavitation method

IntelliCell receives U.S. patent allowance for ultrasonic cavitation method

Hospital-based home care can work for children with cancer

Hospital-based home care can work for children with cancer

FDA approves Ampio’s IND for Optina for treatment of diabetic macular edema

FDA approves Ampio’s IND for Optina for treatment of diabetic macular edema

Mitsubishi Tanabe Pharma in-licenses CETP inhibitor to Dezima Pharma

Mitsubishi Tanabe Pharma in-licenses CETP inhibitor to Dezima Pharma

Gene therapy improves vision but does not halt progression of cell loss

Gene therapy improves vision but does not halt progression of cell loss

Kaiser Permanente study examines increasing prevalence of undervaccination

Kaiser Permanente study examines increasing prevalence of undervaccination

Cordis presents two-year STROLL study results at ISET 2013

Cordis presents two-year STROLL study results at ISET 2013

FDA approves Allergan’s BOTOX to treat overactive bladder

FDA approves Allergan’s BOTOX to treat overactive bladder

Researchers disagree over ethics of HIV treatment clinical trial in Africa, Nature reports

Researchers disagree over ethics of HIV treatment clinical trial in Africa, Nature reports

Enrollment complete in GlycoMimetics’ GMI-1070 Phase 2 study for sickle cell disease

Enrollment complete in GlycoMimetics’ GMI-1070 Phase 2 study for sickle cell disease

SyNAPSe® Trial by BHR Pharma deemed to have no safety issues according to DSMB

SyNAPSe® Trial by BHR Pharma deemed to have no safety issues according to DSMB

New menu of 61 genetically engineered E. coli strains may improve efficacy of vaccines

New menu of 61 genetically engineered E. coli strains may improve efficacy of vaccines

QrxPharma to resubmit MOXDUO NDA with FDA

QrxPharma to resubmit MOXDUO NDA with FDA

Reviews show little evidence of widespread efficacy of mobile health interventions

Reviews show little evidence of widespread efficacy of mobile health interventions

Tzamal Medical, Duchesnay partner to distribute and sell Diclectin for management of NVP

Tzamal Medical, Duchesnay partner to distribute and sell Diclectin for management of NVP

Top-line results from Amgen’s Aranesp Phase 3 trial on heart failure and anemia

Top-line results from Amgen’s Aranesp Phase 3 trial on heart failure and anemia

Speech training holds promise for cochlear implant recipients

Speech training holds promise for cochlear implant recipients

Elan, Biogen Idec submit applications to FDA and EMA for updation of TYSABRI labels

Elan, Biogen Idec submit applications to FDA and EMA for updation of TYSABRI labels

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.